REVVITY, INC.

Overview

Revvity, Inc. is a health-sciences technology and solutions company serving the life sciences and diagnostics markets. Its offerings span reagents, consumables, instruments, services, software and diagnostic solutions, supporting activities from scientific discovery and development through diagnosis [1][2]. The company states its purpose is “to expand the boundaries of human potential through science” [3].

Revvity reports two core segments: Life Sciences, comprising Life Sciences Solutions and Software, and Diagnostics, comprising Immunodiagnostics and Reproductive Health [2]. Its reported geographic markets are the Americas, Europe and Asia [4]. For fiscal 2025, revenue was $2.86 billion [5]. The company reported approximately 11,000 employees and customers in more than 160 countries in its FY2025 results [6].

Revvity launched under its current name in May 2023, following the separation of PerkinElmer’s Life Sciences and Diagnostics businesses from its Applied, Food and Enterprise Services businesses [7]. [1]+8

Products & services

Revvity’s products include diagnostic instruments, reagents, assay platforms and software used in screening and testing. Examples include DELFIA Xpress, a prenatal and maternal screening platform with related assays and LifeCycle software; NeoBase tandem-mass-spectrometry kits and GSP kits for newborn screening; NeoLSD for dried-blood-spot screening of lysosomal disorders; and Vanadis, an automated cell-free DNA non-invasive prenatal testing system.[8]+4 Its EONIS real-time PCR screening supports detection of spinal muscular atrophy, severe combined immunodeficiency and X-linked agammaglobulinemia, while chemagic 360-series systems automate nucleic-acid isolation.[13][14]

Life Sciences offerings include reagents, consumables, instruments, services, technology and licensing, as well as software.[2] Named products include AssayMate, an automated liquid-handler workstation; EnVision Nexus, a multimode plate reader for high-throughput screening; and Living Image Synergy AI, software for imaging acquisition, visualization and analysis.[15]+2 For the three months ended July 5, 2026, reported product revenue was $603.4 million, or 82.7% of total revenue, while service revenue was $126.3 million, or 17.3%.[18] [8]+11

Geographic presence

For the six months ended July 5, 2026, Revvity reported revenue of $641.6 million from the Americas (44.5% of total), $452.1 million from Europe (31.4%), and $347.1 million from Asia (24.1%). For FY2025, revenue was $1,256.0 million from the Americas (44.0%), $825.0 million from Europe (28.9%), and $775.1 million from Asia (27.1%). These are the company’s reported primary geographic markets; the filings do not provide a country-level revenue split.[19]+2

As of December 28, 2025, Revvity marketed products and services in more than 160 countries, with about 2,000 sales and service representatives in approximately 40 countries; it also uses distributors where it lacks a direct commercial presence.[21] Its headquarters are in Waltham, Massachusetts, and it reported approximately 11,000 employees. The filing does not give a regional or country breakdown of employees.[22][23] Company-identified global sites include Waltham, Hopkinton, San Diego, Cambridge, Codolet, Turku, Cracow, Shanghai and Mumbai; this is not presented as a complete facilities inventory.[24] [19]+13

Business segments

Revvity reports two operating segments: **Life Sciences** and **Diagnostics**. Life Sciences serves customers across the life sciences market, while Diagnostics serves clinically oriented customers, particularly in reproductive health and emerging-market diagnostics [1]. From fiscal 2025, Life Sciences comprised Life Sciences Solutions and Software; Diagnostics comprised Immunodiagnostics and Reproductive Health. Life Sciences Solutions includes reagents and consumables, instruments and services, technology, and licensing. Most of Applied Genomics was transferred from Diagnostics to Life Sciences Solutions at the start of fiscal 2025 [2].

By fiscal 2025 segment revenue, Life Sciences contributed approximately **50.1%** ($1.431 billion) and Diagnostics approximately **49.9%** ($1.425 billion) of the $2.856 billion total [25]. The latest available interim figures, for the six months ended July 5, 2026, also show an approximately even split: Life Sciences 50.0% and Diagnostics 50.0% of reported segment revenue [26]. [1]+7

Company history

Perkin-Elmer, the predecessor of Revvity, was founded in 1937 by Richard S. Perkin and Charles W. Elmer as an optics firm. Its early product milestones included a commercially available spectrophotometer in 1944 and a commercial gas chromatograph in 1955.[27]

The company expanded into diagnostics and life sciences through acquisitions, including EUROIMMUN in 2017 and BioLegend in 2021; it also completed acquisitions of Oxford Immunotec and other businesses during 2021.[28]+2 Prahlad Singh succeeded Robert Friel as chief executive officer effective December 30, 2019.[31]

In March 2023, PerkinElmer sold its Applied, Food and Enterprise Services businesses, concentrating the remaining company on life sciences and diagnostics. It adopted the name Revvity, Inc. effective April 26, 2023, and began trading under the ticker RVTY on May 16.[32] [27]+5

Sources

• REVVITY, INC. — Full financial report (2025 Y)
  19 citations

  [1][2][4][5][8][9][10][11][12][13][14][15][16][17][20][21][22][23][25]
• www.revvity.com[3]
• ir.revvity.com[6]
• ir.revvity.com[7]
• REVVITY, INC. — Full financial report (2026 Q 2)
  3 citations

  [18][19][26]
• jobs.revvity.com[24]
• collection.sciencemuseumgroup.org.uk[27]
• ir.revvity.com[28]
• ir.revvity.com[29]
• ir.revvity.com[30]
• news.revvity.com[31]
• news.revvity.com[32]